Current Pain and Headache Reports

, Volume 12, Issue 3, pp 207–212 | Cite as

Putative mechanisms of the relationship between obesity and migraine progression

Article

Abstract

Studies suggest that obesity is associated with migraine progression from an episodic into a chronic form. We discuss putative mechanisms to justify this relationship. Several of the inflammatory mediators that are increased in obese individuals are important in migraine pathophysiology, including interleukins and calcitonin gene-related peptide. Both migraine and obesity are prothrombotic states. Substances that are important in metabolic control are nociceptive at certain levels. Hypothalamic dysfunction in the orexin pathways seems to be a risk factor for both conditions. In addition, we discuss the importance of metabolic syndrome and autonomic dysfunction in modulating the obesity/migraine progression relationship.

Keywords

Obesity Migraine Chronic Migraine Migraine With Aura Chronic Daily Headache 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Scher AI, Stewart WF, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497–506.PubMedCrossRefGoogle Scholar
  2. 2.
    Lipton RB, Bigal ME: Migraine: epidemiology, impact, and risk factors for progression. Headache 2005, 45(Suppl 1):S3–S13PubMedCrossRefGoogle Scholar
  3. 3.
    Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Silberstein SD, Lipton RB, Sliwinski M: Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871–875.PubMedGoogle Scholar
  5. 5.
    Saper JR: The mixed headache syndrome: a new perspective. Headache 1982, 22:284–286.PubMedCrossRefGoogle Scholar
  6. 6.
    Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Katsarava Z, Muessig M, Dzagnidze A, et al.: Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005, 25:12–15.PubMedCrossRefGoogle Scholar
  8. 8.
    National Center for Chronic Disease Prevention and Health Promotion: Overweight and obesity: obesity trends. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/index.htm. Accessed June 18, 2006.
  9. 9.
    Yan LL, Daviglus ML, Liu K, et al.: Midlife body mass index and hospitalization and mortality in older age. JAMA 2006, 295:190–198.PubMedCrossRefGoogle Scholar
  10. 10.
    World Health Organization: Obesity and overweight. Global strategy on diet, physical activity, and health. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en. Accessed August 19, 2006.
  11. 11.
    Wang Y, Mi J, Shan XY, et al.: Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007, 31:177–188.CrossRefGoogle Scholar
  12. 12.
    Finkelstein EA, Fiebelkorn IC, Wang G: National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff 2003, Suppl Web Exclusives: W3-219-226.Google Scholar
  13. 13.
    Bigal ME, Liberman JN, Lipton RB: Obesity and migraine: a population study. Neurology 2006, 66:545–550.PubMedCrossRefGoogle Scholar
  14. 14.
    Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not for chronic tension-type headache. Neurology 2006, 67:252–257.PubMedCrossRefGoogle Scholar
  15. 15.
    Bigal ME, Tsang A, Loder E, et al.: Body mass index and primary headaches. The AMPP study. Arch Intern Med 2007, 167:1964–1970.PubMedCrossRefGoogle Scholar
  16. 16.
    Bigal ME, Lipton RB, Holland PR, Goadsby PJ: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851–1861.PubMedCrossRefGoogle Scholar
  17. 17.
    Peres MF, Lerário DD, Garrido AB, Zukerman E: Primary headaches in obese patients. Arq Neuropsiquiatr 2005, 63:931–933.PubMedGoogle Scholar
  18. 18.
    Tietjen GE, Peterlin BL, Brandes JL, et al.: Depression and anxiety: effect on the migraine-obesity relationship. Headache 2007, 47:866–875.PubMedCrossRefGoogle Scholar
  19. 19.
    Breslau N, Lipton RB, Stewart WF, et al.: Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003, 60:1308–1312.PubMedGoogle Scholar
  20. 20.
    Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993, 5:159–177.PubMedGoogle Scholar
  21. 21.
    Moskowitz MA: Neurogenic inflammation in the patho-physiology and treatment of migraine. Neurology 1993, 43(Suppl 3):S16–S20.PubMedGoogle Scholar
  22. 22.
    Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Goadsby PJ, Macdonald GJ: Extracranial vasodilatation mediated by VIP (vasoactive intestinal polypeptide). Brain Res 1985, 329:285–288.PubMedCrossRefGoogle Scholar
  24. 24.
    Sarchielli P, Alberti A, Baldi A, et al.: Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46:200–207.PubMedCrossRefGoogle Scholar
  25. 25.
    Welch KM, Brandes AW, Salerno L, Brandes JL: C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006, 46:197–199.PubMedCrossRefGoogle Scholar
  26. 26.
    Flier JS: The adipocyte: storage depot or node on the energy information superhighway? Cell 1995, 80:15–18.PubMedCrossRefGoogle Scholar
  27. 27.
    Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145–1158.PubMedCrossRefGoogle Scholar
  28. 28.
    Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516–520.PubMedCrossRefGoogle Scholar
  29. 29.
    Curat CA, Wegner V, Sengenes C, et al.: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744–747.PubMedCrossRefGoogle Scholar
  30. 30.
    Gram DX, Hansen AJ, Wilken M, et al.: Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 2005, 153:963–969.PubMedCrossRefGoogle Scholar
  31. 31.
    Kurth T, Gaziano JM, Cook NR, et al.: Migraine and risk of cardiovascular disease in women. JAMA 2006, 296:283–291.PubMedCrossRefGoogle Scholar
  32. 32.
    Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al.: Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447–1455.PubMedGoogle Scholar
  33. 33.
    D’Amico D, Moschiano F, Leone M, et al.: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998, 18:618–621.PubMedCrossRefGoogle Scholar
  34. 34.
    Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516–520.PubMedCrossRefGoogle Scholar
  35. 35.
    Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917–2921.PubMedCrossRefGoogle Scholar
  36. 36.
    Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol 2006, 64:355–365.Google Scholar
  37. 37.
    Shoji T, Koyama H, Fukumoto S, et al.: Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006, 188:190–195.PubMedCrossRefGoogle Scholar
  38. 38.
    Siegel JM: Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004, 55:25–48.CrossRefGoogle Scholar
  39. 39.
    Kajiyama S, Kawamoto M, Shiraishi S: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally administered orexins in diabetic neuropathic pain model rats. Brain Res 2005, 1044:76–86.PubMedCrossRefGoogle Scholar
  40. 40.
    Baranowska B, Wolinska-Witort E, Martynska M, et al.: Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett 2005, 26:714.Google Scholar
  41. 41.
    Bartsch T, Levy MJ, Knight YE, Goadsby PJ: Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004, 109:367–378.PubMedCrossRefGoogle Scholar
  42. 42.
    Holland PR, Akerman S, Goadsby PJ: Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005, 315:1380–1385.PubMedCrossRefGoogle Scholar
  43. 43.
    Haffner SM: Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 2006, 119(Suppl 1):S3–S9.PubMedCrossRefGoogle Scholar
  44. 44.
    Loevinger BL, Muller D, Alonso C, Coe CL: Metabolic syndrome in women with chronic pain. Metabolism 2007, 56:87–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Scher AI, Terwindt GM, Picavet HS, et al.: Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 2005, 64:614–620.PubMedGoogle Scholar
  46. 46.
    Chrysohoou C, Pitsavos C, Skoumas J, et al.: The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population; the ATTICA study. Int J Cardiol 2007, 122:29–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Carnethon MR, Golden SH, Folsom AR, et al.: Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study, 1987–1998. Circulation 2003, 107:2190–2195.PubMedCrossRefGoogle Scholar
  48. 48.
    Liatis S, Tentolouris N, Katsilambros N: Cardiac autonomic nervous system activity in obesity. Pediatr Endocrinol Rev 2004, 1(Suppl 3):476–483.PubMedGoogle Scholar
  49. 49.
    Peroutka SJ: Migraine: a chronic sympathetic nervous system disorder. Headache 2004, 44:53–64.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Global Director for Scientific Affairs, NeuroscienceMerck Research LaboratoriesWhite-house StationUSA

Personalised recommendations